Last week, Hawley introduced legislation that would remove the U.S. Food and Drug Administration’s approval for mifepristone, the first pill used in the two-drug medication abortion regimen.

Hawley argues the drug is unsafe and that regulators ignored mounting evidence of complications. Critics say the proposal is little more than political theater aimed at restricting abortion access nationwide.

As usual, the truth is tangled somewhere between deeply held moral convictions, disputed scientific claims, and a healthy dose of Washington politics.

Medication abortion now accounts for a majority of abortions in the United States, which means the stakes in this fight are enormous. If Hawley’s bill passed, it could dramatically reshape abortion access nationwide.

But the deeper question goes beyond abortion itself. It touches on something fundamental: Should Congress step in and overrule the FDA’s drug approval decisions?

The Case for Hawley’s Bill: Safety Concerns and Accountability

Supporters of Hawley’s proposal argue that the debate over mifepristone is fundamentally about patient safety and regulatory accountability.

Mifepristone was approved by the FDA in 2000 under a special regulatory pathway designed for drugs treating serious illnesses. Critics have long argued that pregnancy is not an illness and that the approval process was politically influenced from the start. For those critics, the drug’s original approval was controversial even before it entered the market.

Over the years the FDA gradually loosened restrictions on the drug. Early safeguards required in-person physician supervision and strict reporting of complications. Those safeguards have steadily been relaxed. Today the drug can be prescribed via telemedicine and shipped through the mail in many cases.

Supporters of Hawley’s bill believe these changes were reckless.

They point to studies suggesting higher complication rates than previously reported, including emergency room visits, severe bleeding, and infections. Critics of the current system also argue that adverse events are underreported because federal reporting requirements were scaled back.

In their view, the FDA effectively lowered the guardrails around a powerful drug without adequate transparency.

Then there’s the moral dimension. For pro-life advocates, mifepristone isn’t merely another medication. It’s a drug designed specifically to terminate human life in early pregnancy. That reality shapes how supporters view the risk calculations involved.

If the drug is both morally controversial and medically disputed, supporters argue, then Congress has every right—perhaps even an obligation—to intervene.

From that perspective, Hawley’s bill isn’t political interference. It’s overdue oversight.

The Case Against the Bill: Scientific Consensus and Institutional Stability

Opponents of Hawley’s proposal see the issue very differently. In their view, the bill represents a direct political attack on science-based regulation.

Mifepristone has been used in the United States for more than two decades and in many other countries even longer. During that time millions of women have used the medication, giving researchers a large body of data on its safety profile.

Most major medical organizations say the drug is extremely safe when used according to guidelines. Serious complications occur in a small fraction of cases, and the rate of severe outcomes is generally considered lower than many common medical procedures.

Critics therefore argue that revoking FDA approval would ignore a substantial body of scientific evidence.

Beyond the scientific debate lies a broader institutional concern. The FDA’s role is to evaluate drugs based on safety and effectiveness using rigorous clinical evidence. If Congress begins overturning drug approvals for political reasons, critics warn, it could destabilize the entire regulatory framework.

Imagine the precedent.

If lawmakers can revoke approval for mifepristone because of moral objections, a future Congress might target other controversial treatments: vaccines, hormone therapies, or psychiatric medications.

Once the door is opened to politically driven drug bans, the pharmaceutical approval process could become another partisan battleground.

Opponents also argue that banning mifepristone would not end medication abortion entirely. Doctors could still use misoprostol alone, which is less effective but widely available. In that sense, the bill might create new medical complications without achieving its intended policy goals.

For critics, Hawley’s proposal risks sacrificing regulatory stability in pursuit of a political objective.

The Political Reality: Why This Bill Matters Even If It Doesn’t Pass

Even supporters of Hawley’s bill recognize that passing it will be difficult.

Major federal legislation requires broad congressional support, and abortion remains one of the most polarizing issues in American politics. The Senate’s legislative rules alone make sweeping national restrictions extremely difficult to enact.

But legislation like this is often about shaping the national debate, not just passing a law.

Since the Supreme Court overturned Roe v. Wade, the abortion battle has shifted dramatically. State laws now dominate the landscape, but medication abortion has emerged as a new focal point. Because pills can be prescribed remotely and shipped across state lines, they complicate state-level restrictions.

In many ways, the fight over mifepristone is the next major chapter in the abortion policy debate.

By introducing the bill, Hawley forces lawmakers, regulators, and the public to grapple with uncomfortable questions:

• Did the FDA relax safety rules too quickly?
• Are complication rates accurately tracked?
• Should medication abortion be regulated differently from surgical procedures?

Even if the bill never becomes law, it pushes those questions back into the spotlight.

And in Washington, that alone can shift policy discussions in meaningful ways.

Final Verdict: Congress May Need to Step In, But Carefully

There are legitimate concerns about Congress interfering in scientific regulatory decisions. The FDA exists precisely so that drug approvals are based on medical evidence rather than political winds.

That concern shouldn’t be dismissed lightly.

But the debate over mifepristone is unusual in several ways. The drug was approved under extraordinary political pressure in 2000, its regulatory framework has been repeatedly modified, and serious disagreements remain over how adverse events are tracked and reported.

Those unresolved questions justify stronger scrutiny.

In addition, abortion isn’t a typical pharmaceutical issue. It involves profound ethical questions about human life that I and millions of Americans believe the federal government has a duty to address. Ignoring that moral dimension in the name of bureaucratic deference would also be a mistake.

For those reasons, Hawley’s effort to revisit the FDA’s approval deserves serious consideration.

That doesn’t necessarily mean Congress should casually overturn every controversial drug approval. Doing so would indeed risk politicizing the pharmaceutical system.

However, when a drug sits at the intersection of contested science, evolving regulatory standards, and profound moral debate, congressional oversight is not only appropriate; it may be necessary.

In short, the concerns about undermining the FDA are real. But the concerns surrounding mifepristone are real as well.

Given the gravity of the issue and the lingering questions about safety and oversight, Congress has a reasonable case for stepping in and reassessing the drug’s approval.

Whether Hawley’s specific bill is the final answer remains to be seen. But the broader push to reevaluate mifepristone is not unreasonable.

Sometimes even the FDA deserves a second look.